Short-term effects of intravitreal bevacizumab on cornea and anterior chamber

Current Eye Research

Volumn 39, Issue 10, 2014, Pages 989-993

  Güler, Mete ^a   Çapkin, Musa ^a   Şimşek, Ali ^a   Bilak, Şemsettin ^a   Bilgin, Burak ^a   Reyhan, Ali Hakim ^a   Firat, Müge ^a  

^a ADIYAMAN UNIVERSITY   (Turkey)

Author keywords

Anterior chamber depth; bevacizumab; central corneal thickness; intraocular pressure; iridocorneal angle; simulated keratometry

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ANTERIOR EYE CHAMBER DEPTH; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL CORNEAL THICKNESS; CENTRAL RETINA VEIN OCCLUSION; CENTRAL SEROUS RETINOPATHY; CLINICAL ARTICLE; DIABETIC MACULAR EDEMA; DRUG EFFECT; FEMALE; GOLDMANN APPLANATION TONOMETER; HUMAN; INTERVENTION STUDY; INTRAOCULAR PRESSURE; KERATOMETRY; MALE; PROSPECTIVE STUDY; SINGLE DRUG DOSE; VITREOUS HEMORRHAGE; ANTAGONISTS AND INHIBITORS; ANTERIOR EYE CHAMBER; CORNEA; CORNEAL PACHYMETRY; DRUG EFFECTS; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; IRIS; MIDDLE AGED; OCULOPLETHYSMOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY; ORGAN SIZE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTERIOR CHAMBER; ANTIBODIES, MONOCLONAL, HUMANIZED; CORNEA; CORNEAL PACHYMETRY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTERVENTION STUDIES; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; IRIS; MALE; MIDDLE AGED; ORGAN SIZE; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TONOMETRY, OCULAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84907193446     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2014.888452     Document Type: Article

References (31)

1. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011;56:95-113.
2. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelveweek results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-1047.
3. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26:999-1005.
4. Priglinger SG, Wolf AH, Kreutzer TC, Kook D, Hofer A, Strauss RW, et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina 2007;27:1004-1012.
5. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, Hamrah P, Jurkunas UV, Pineda 2nd R, et al. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol 2009;127:381-389.
6. Ozgurhan EB, Agca A, Kara N, Yuksel K, Demircan A, Demirok A. Topical application of bevacizumab as an adjunct to recurrent pterygium surgery. Cornea 2013;32: 835-838.
7. Meyer CH, Krohne TU, Holz FG. Intraocular pharmacokinetics after a single intravitreal injection of 1.5mg versus 3.0mg of bevacizumab in humans. Retina 2011;31: 1877-1884.
8. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008;146:508-512.
9. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006; 26:257-261.
10. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:270-274.
11. Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A. Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology 2012;119: 2587-2591.
12. Chiang CC, Chen WL, Lin JM, Tsai YY. Effect of bevacizumab on human corneal endothelial cells: a sixmonth follow-up study. Am J Ophthalmol 2008;146: 688-691.
13. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 2000;41:2514-2522.
14. Güler M, Yilmaz T, Ozercan I, Elkiran T. The inhibitory effects of trastuzumab on corneal neovascularization. Am J Ophthalmol 2009;147:703-708.
15. Yoeruek E, Spitzer MS, Tatar O, Aisenbrey S, Bartz- Schmidt KU, Szurman P. Safety profile of bevacizumab on cultured human corneal cells. Cornea 2007;26:977-982.
16. Savini G, Barboni P, Carbonelli M, Hoffer KJ. Comparison of methods to measure corneal power for intraocular lens power calculation using a rotating Scheimpflug camera. J Cataract Refract Surg 2013;39:598-604.
17. Leng C, Feiz V, Modjtahedi B, Moshirfar M. Comparison of simulated keratometric changes induced by custom and conventional laser in situ keratomileusis after myopic ablation: retrospective chart review. J Cataract Refract Surg 2010;36:1550-1555.
18. Jin ZY, Zhu D, Tao Y, Wong IY, Jonas JB. Meta-analysis of the effect of intravitreal bevacizumab versus intravitreal triamcinolone acetonide in central retinal vein occlusion. Ocul Pharmacol Ther 2013;29:826-831.
19. Zhang XL, Chen J, Zhang RJ, Wang WJ, Zhou Q, Qin XY. Intravitreal triamcinolone versus intravitreal bevacizumab for diabetic macular edema: a meta-analysis. Int J Ophthalmol 2013;6:546-552.
20. Alkin Z, Perente I, Altan C, Konstantinidis A, Ozkaya A, Yuksel K, et al. Changes in anterior segment morphology after intravitreal injection of bevacizumab and bevacizumab- triamcinolone acetate combination. Eur J Ophthalmol 2013;23:504-509.
21. Sobac G, Güngö r R, Ozge G. Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: a comparative clinical study. Int J Ophthalmol 2013;6:211-215.
22. Wehrli SJ, Tawse K, Levin MH, Zaidi A, Pistilli M, Brucker AJ. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab. Retina 2012;32:1295-1301.
23. Cacciamani A, Oddone F, Parravano M, Scarinci F, Di Nicola M, Lofoco G. Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length. Jpn J Ophthalmol 2013;57:63-67.
24. Hoang QV, Tsuang AJ, Gelman R, Mendonca LS, Della Torre KE, et al. Clinical predictors of sustained intraocular pressure elevation due to intravitreal antivascular endothelial growth factor therapy. Retina 2013;33: 179-187.
25. Mathalone N, Arodi-Golan A, Sar S, Wolfson Y, Shalem M, Lavi I, et al. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2012;250:1435-1440.
26. Vadlapudi DA, Mitra AK. Sustained delivery of biologics to back of the eye. J Biotechnol Biomater 2013;3:e122.
27. Tseng JJ, Vance SK, Della Torre KE, Mendonca LS, Cooney MJ, Klancnik JM, et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucom 2012;21:241-247.
28. Bakri SJ, Larson TA, Edwards AO. Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol 2008;246:779-781.
29. Sniegowski M, Mandava N, Kahook MY. Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis. Open Ophthalmol J 2010;4:28-29.
30. Yoshida N, Hisatomi T, Ikeda Y, Kohno R, Murakami Y, Imaki H, et al. Intravitreal bevacizumab treatment for neovascular glaucoma: histopathological analysis of trabeculectomy specimens. Graefes Arch Clin Exp Ophthalmol 2011;249:1547-1552.
31. Matsuyama K, Ogata N, Jo N, Shima C, Matsuoka M, Matsumura M. Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab. Jpn J Ophthalmol 2009;53:243-248.